IGC Pharma (IGC) AI Stock Analysis

• Market Cap: $35.78M
• Dividend Yield: N/A
• Average Volume (3M): 715.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: 24.95%
• EPS Growth: 61.65%
• Country: US
• Employees: 67
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 91,959,114
• 10 Day Avg. Volume: 826,885
• 30 Day Avg. Volume: 715,709
• PEG Ratio: 0.05
• Price to Book (P/B): 3.45
• Price to Sales (P/S): 17.16
• P/FCF Ratio: -4.13
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 17.25
• Enterprise Value/Gross Profit: 37.52
• Enterprise Value/Ebitda: -3.60
• 1Y Price Target: $4.50
• Price Target Upside: 1116.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.50 ▲(35.14% Upside)

IGC Pharma's overall stock score is primarily impacted by its weak financial performance, characterized by significant profitability and cash flow challenges. The technical analysis provides a neutral outlook, while the valuation is constrained by negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Clinical Trial Expansion

The expansion of the CALMA trial to new sites accelerates recruitment and advances the timeline, enhancing IGC Pharma's potential to address unmet needs in Alzheimer's treatment.

Innovative Drug Development

IGC-1C's potential to halt Alzheimer's progression before irreversible damage represents a paradigm shift, expanding IGC's pipeline and therapeutic reach.

Patent Allowance

Securing a patent strengthens IGC's intellectual property portfolio, potentially opening new revenue streams and enhancing competitive positioning in niche markets.

Negative Factors

Profitability Challenges

Severe profitability issues reflect operational challenges, limiting IGC's ability to reinvest in growth and innovation, potentially hindering long-term sustainability.

Cash Flow Difficulties

Persistent cash outflows indicate financial strain, impacting IGC's ability to fund operations and strategic initiatives, posing a risk to long-term viability.

Negative Return on Equity

A negative ROE suggests inefficiency in using equity capital, potentially deterring investment and affecting IGC's capacity to attract new funding.

IGC Pharma Business Overview & Revenue Model

Company Description

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

How the Company Makes Money

IGC Pharma generates revenue through several key streams, primarily by developing and commercializing its proprietary cannabis-derived pharmaceuticals. The company's revenue model includes income from product sales, partnerships with larger pharmaceutical firms for distribution and co-development of its therapies, and potential royalties from licensing agreements. Additionally, IGC may benefit from grants and funding for research and development in innovative drug formulations. Significant partnerships with research institutions and collaborations with industry leaders further enhance its revenue potential by facilitating access to broader markets and improving product validation.

IGC Pharma Financial Statement Overview

Summary

IGC Pharma is experiencing financial difficulties across all verticals. Despite modest revenue growth, the company faces significant profitability and cash flow challenges, with deeply negative profit margins and cash outflows. The low leverage is a positive aspect, but the negative return on equity and substantial losses are major concerns.

Income Statement

IGC Pharma's income statement shows a modest revenue growth rate of 4.41% TTM, but the company is struggling with profitability. The gross profit margin is reasonable at 48.70%, yet the net profit margin is significantly negative at -560.27%, indicating substantial losses. The EBIT and EBITDA margins are also deeply negative, reflecting operational challenges. Overall, while there is some revenue growth, the company faces severe profitability issues.

Balance Sheet

The balance sheet of IGC Pharma indicates a low debt-to-equity ratio of 0.0376, suggesting minimal leverage, which is a positive aspect. However, the return on equity is negative at -102.29%, highlighting the company's inability to generate profits from shareholders' equity. The equity ratio is not provided, but the low leverage is a strength amidst the overall weak financial performance.

Cash Flow

IGC Pharma's cash flow statement reveals negative operating and free cash flows, with a free cash flow growth rate of -7.00% TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Although the free cash flow to net income ratio is slightly positive at 1.05, the overall cash flow situation is concerning, with persistent cash outflows.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.33M	1.27M	1.34M	911.00K	397.00K	898.00K
Gross Profit	610.00K	619.00K	733.00K	442.00K	194.00K	113.00K
EBITDA	-6.36M	-6.83M	-9.16M	-10.91M	-14.78M	-8.25M
Net Income	-6.34M	-7.12M	-13.00M	-11.51M	-15.02M	-8.81M
Balance Sheet
Total Assets	7.94M	8.75M	9.90M	17.18M	26.83M	35.87M
Cash, Cash Equivalents and Short-Term Investments	454.00K	405.00K	1.20M	3.35M	10.46M	14.63M
Total Debt	202.00K	238.00K	345.00K	481.00K	488.00K	985.00K
Total Liabilities	1.86M	2.42M	2.58M	2.27M	2.94M	3.06M
Stockholders Equity	6.08M	6.33M	7.32M	14.91M	23.89M	32.80M
Cash Flow
Free Cash Flow	-4.70M	-5.28M	-5.71M	-7.67M	-8.20M	-12.39M
Operating Cash Flow	-4.45M	-4.79M	-5.20M	-7.05M	-7.46M	-10.80M
Investing Cash Flow	269.00K	-442.00K	-317.00K	-235.00K	-742.00K	3.39M
Financing Cash Flow	2.79M	4.45M	3.52M	100.00K	4.14M	14.69M

IGC Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IGC, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.41, and above the 200-day MA of 0.34, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.11 is Neutral, neither overbought nor oversold. The STOCH value of 15.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IGC.

IGC Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DYAI	46 Neutral	$38.00M	-5.64	-422.64%	―	129.20%	30.36%
IGC	44 Neutral	$35.78M	-4.85	-90.87%	―	24.95%	61.65%
ELUT	44 Neutral	$39.00M	-0.87	―	―	-14.92%	72.81%
LVTX	44 Neutral	$42.75M	-1.54	-101.50%	―	-32.06%	16.38%
VRCA	43 Neutral	$32.68M	―	―	―	5.72%	55.79%
PLUR	38 Underperform	$28.87M	-1.01	―	―	309.82%	11.80%

IGC Pharma Corporate Events

IGC Pharma Subsidiary Signs Asset Sale Agreement

On September 29, 2025, IGC Pharma‘s subsidiary, Holi Hemp LLC, entered into a Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest Inc. The agreement involves the sale of equipment, inventory, and a facility for approximately $2.7 million, subject to adjustments. The transaction includes preferential supply rights for IGC Pharma and a 10% entitlement on net proceeds if the buyer sells the business within five years.

The most recent analyst rating on (IGC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.

Igc Pharma’s Risky Venture: Navigating Financial Instability Amid Bitcoin Investment Plans

Igc Pharma, Inc. faces potential financial instability as management considers investing in digital assets, such as bitcoin, which are known for their significant price volatility and regulatory uncertainties. The evolving legal landscape and operational risks, including cybersecurity threats and custody issues, further compound these challenges. Additionally, liquidity constraints and tax implications could exacerbate the financial impact, leading to increased earnings volatility. Consequently, these factors could adversely affect the company’s financial condition and operational results, with no guarantee of positive returns from such investments.